Patents by Inventor Yibin Zeng

Yibin Zeng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12054484
    Abstract: Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (Ia1?): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: August 6, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Junfa Fan, Jaroslaw Kalisiak, Rebecca M. Lui, Venkat Reddy Mali, Jeffrey P. McMahon, Jay P. Powers, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
  • Publication number: 20240132495
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula I including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: November 29, 2023
    Publication date: April 25, 2024
    Applicant: CHEMOCENTRYX, INC.
    Inventors: Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Darren J. McMURTRIE, Ryan J. SCAMP, Ju YANG, Yibin ZENG, Penglie ZHANG
  • Publication number: 20240115682
    Abstract: Provided herein are methods of treating certain cancers comprising administering to the subject in need there of an effective amount of a compound of Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Ra, and Rb are as defined herein.
    Type: Application
    Filed: November 15, 2023
    Publication date: April 11, 2024
    Inventors: Shijie LI, Marta VILALTA-COLOMER, Yibin ZENG, Penglie ZHANG
  • Publication number: 20240100041
    Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.
    Type: Application
    Filed: December 6, 2023
    Publication date: March 28, 2024
    Applicant: CHEMOCENTRYX, INC.
    Inventors: James CAMPBELL, Israel CHARO, Thomas SCHALL, Rajinder SINGH, Yibin ZENG, Penglie ZHANG
  • Patent number: 11883391
    Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: January 30, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: James Campbell, Israel Charo, Thomas Schall, Rajinder Singh, Yibin Zeng, Penglie Zhang
  • Patent number: 11866429
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: January 9, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Darren J. McMurtrie, Ryan J. Scamp, Ju Yang, Yibin Zeng, Penglie Zhang
  • Patent number: 11834452
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: December 5, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Junfa Fan, Antoni Krasinski, Christopher W. Lange, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
  • Publication number: 20230382894
    Abstract: Compounds are provided having formula (I): wherein the groups/letters R1a, R1b, m, R2, R3, R4, X, Y, A, B, n, q, L and Q, have the meanings provided herein. The compounds are useful as CCR4 antagonists and are useful in treated diseases and conditions modulated by CCR4 activity.
    Type: Application
    Filed: April 18, 2023
    Publication date: November 30, 2023
    Inventors: Pingchen FAN, Rebecca M. LUI, Ryan J. SCAMP, Ju YANG, Yu WANG, Yibin ZENG, Penglie ZHANG
  • Publication number: 20230381167
    Abstract: Provided herein is a free base crystalline form of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the crystalline free base form of Compound 1 described herein.
    Type: Application
    Filed: April 24, 2023
    Publication date: November 30, 2023
    Inventors: Rajinder SINGH, Kwok YAU, Yibin ZENG, Penglie ZHANG, Rebecca M. LUI, Antoni KRASINSKI
  • Patent number: 11807609
    Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: November 7, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Rebecca M. Lui, Venkat Reddy Mali, Rajinder Singh, Yibin Zeng, Penglie Zhang
  • Publication number: 20230339851
    Abstract: Provided are sulfonamide compounds having formula (I): or a pharmaceutically acceptable salt thereof, wherein R, R1, R2, R3, R4 and the subscripts n and m have the meanings provided in the specification. The compounds are useful for treating diseases and conditions associated with CXCR6 activity.
    Type: Application
    Filed: March 20, 2023
    Publication date: October 26, 2023
    Inventors: Hiufung CHU, Pingchen FAN, Yandong LI, Viengkham MALATHONG, Jay POWERS, Hiroko TANAKA, Yibin ZENG, Penglie ZHANG
  • Publication number: 20230322731
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: June 12, 2023
    Publication date: October 12, 2023
    Inventors: Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Darren J. McMURTRIE, Ryan J. SCAMP, Ju YANG, Yibin ZENG, Penglie ZHANG
  • Patent number: 11773091
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: October 3, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Rajinder Singh, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
  • Patent number: 11713307
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: August 1, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Darren J. McMurtrie, Ryan J. Scamp, Ju Yang, Yibin Zeng, Penglie Zhang
  • Publication number: 20230151002
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Application
    Filed: May 3, 2022
    Publication date: May 18, 2023
    Inventors: Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Viengkham MALATHONG, Venkat Reddy MALI, Sreenivas PUNNA, Rajinder SINGH, Hiroko TANAKA, Yibin ZENG, Penglie ZHANG
  • Publication number: 20230115912
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Application
    Filed: September 13, 2022
    Publication date: April 13, 2023
    Inventors: Pingchen FAN, Christopher W. LANGE, Viengkham MALATHONG, Venkat Reddy MALI, Sreenivas PUNNA, Hiroko TANAKA, Yibin ZENG, Penglie ZHANG
  • Publication number: 20230102258
    Abstract: Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of C5a receptors.
    Type: Application
    Filed: September 26, 2022
    Publication date: March 30, 2023
    Inventors: Pingchen FAN, Kevin Lloyd GREENMAN, Manmohan Reddy LELETI, Yandong LI, Jay POWERS, Hiroko TANAKA, Ju YANG, Yibin ZENG
  • Patent number: 11608336
    Abstract: The present disclosure provides, inter alia, Compounds of Formulae IA, IB, IC, IIA, IIB and IIC or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: March 21, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Rebecca M. Lui, Rajinder Singh, Venkat Reddy Mali, Yibin Zeng, Penglie Zhang
  • Patent number: 11603356
    Abstract: Provided herein is an amorphous form of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the amorphous form of Compound 1, described herein.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: March 14, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Kwok Yau, Kenken Luong, Rajinder Singh, Yibin Zeng, Penglie Zhang, Manmohan Reddy Leleti, Rebecca M. Lui
  • Publication number: 20230044941
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: January 14, 2022
    Publication date: February 9, 2023
    Inventors: Pingchen FAN, Christopher LANGE, Venkat Reddy MALI, Darren J. McMURTRIE, Viengkham MALATHONG, Sreenivas PUNNA, Rajinder SINGH, Ju YANG, Yibin ZENG, Penglie ZHANG